| Similar Articles |
|---|
 |
The Motley Fool
July 22, 2005
Stephen D. Simpson |
Big Miss Afflicts Affymetrix Gee-whiz technology doesn't always mean gee-whiz growth. While the facilitator of genetics research and drug development enjoyed has recovered significantly from its lows, long-term investors saw another market thrashing on a disappointing outlook.   |
The Motley Fool
August 7, 2006
Stephen D. Simpson |
Affymetrix: Price Always Matters Affymetrix has legit technology, but that doesn't mean it has infinite value for investors. |
The Motley Fool
January 31, 2006
John Bluis |
Affymetrix: Far, Far Array Investors who enjoy companies that are consistent with guidance may have some interest in this company that provides tools for use in genomics-related research. Unfortunately, this year the consistency was in reporting disappointing results. |
The Motley Fool
October 24, 2008
Brian Orelli |
Affymetrix Has Trouble Turning Around The problem is that Affymetrix doesn't sell sequencers, and no one seems to want the genome and RNA analyzers that it does sell. |
The Motley Fool
July 23, 2011 |
Affymetrix Earnings Preview Affymetrix will unveil its latest earnings on Wednesday, July 27. |
The Motley Fool
April 24, 2006
John Bluis |
Affymetrix Gets Chipped Again The woes continue for Affymetrix, the leading provider of high-density microarray products. Investors must decide if this is a management issue -- as indeed it appears to be. |
The Motley Fool
January 28, 2005
Karl Thiel |
Affymetrix Raking in the Chips The life sciences research chip maker is enjoying green pastures in the gene business. The company announced fourth-quarter revenues and profits that handily beat consensus expectations, and then gave an upbeat view of 2005. |
The Motley Fool
April 27, 2007
Brian Orelli |
Making Money Off Your Competitors Affymetrix is looking appealing with a few new products and potential revenues from an unlikely source. Investors, take note. |
The Motley Fool
July 25, 2008
Brian Orelli |
Affymetrix Astounds, in the Worst Way After taking a beating last quarter, biochip maker Affymetrix got pounded again in the second quarter, as its turnaround from the lows of 2006 fizzled out. |
Wired
June 2000
Brian Alexander |
Biopoly Money Patents and strong-arm tactics are helping make Affymetrix the Intel of biochips. Along the way, Affy wants to turn DNA into a proprietary system. |
Bio-IT World
July 2005
Johan Bostrom |
Affymetrix to Acquire ParAllele The companies have been working together for the past two years, with Affymetrix using ParAllele's assay technology with the Affymetrix GeneChip technology. Affymetrix expects to strengthen its assay R&D capabilities and add knowledge in specific assay capabilities through the acquisition. |
The Motley Fool
October 25, 2007
Brian Orelli |
Turnaround at Affymetrix Affymetrix announces it is continuing its turnaround from an abysmal 2006 with another strong quarter. |
The Motley Fool
August 6, 2008
Brian Orelli |
Illumina Grabs Some Cash With biochip maker Illumina hitting 52-week highs, it seems inevitable that the company would do a secondary offering to grab some cash -- about $300 million, as it turns out. |
Bio-IT World
September 2004 |
Products New product news: Portfolio of Proteins Accelerates Research... Affymetrix Maps Out SNPs... Predictive Plug-Ins for Chemists... etc. |
The Motley Fool
November 12, 2008
Brian Orelli |
Affymetrix Gets Specific The biochip maker announces that it will acquire privately held Panomics for $73 million in cash. |
The Motley Fool
October 23, 2006
Jack Uldrich |
Is Microsoft on Drugs? If the company uses its new BioIT Alliance not simply to push its existing software, but also to better understand what biotech customers need and want, Microsoft's new drug habit could even provide its long-suffering shareholders a little high. |
The Motley Fool
April 25, 2008
Brian Orelli |
Affymetrix Learns About Inertia Slower sales of its older chips drag down growth. |
